Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival
- 679 Downloads
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) participate in tumorigenesis, and their association with disease outcome is highly controversial. The present study investigates the influence of MMP-1, MMP-9 and TIMP-2 on different clinicopathologic variables and disease-free survival (DFS) of patients with prostate carcinoma.
Hundred and forty-five cases are included in the study, and levels of MMP/TIMP expressions are assessed in three tissue compartments (i.e., tumor, stroma and normal glands) with immunohistochemistry.
Matrix metalloproteinase-1 expression in tumor cells was associated with lower Gleason scores, pretreatment prostate-specific antigen levels and lower incidence of vascular, perineural and extracapsular invasions. Moreover, MMP-9 positivity and TIMP-2 expression in normal glands were correlated with lower Gleason patterns and early stage at presentation. Expression of MMP in tumor cells and the presence of TIMP-2 in normal glands were associated with better DFS.
Variability of MMP/TIMP expressions from case to case makes it difficult to evaluate their impact on clinical outcome. However, these proteins might be new and promising targets for prostate cancer therapy in the future.
KeywordsMatrix metalloproteinases Tissue inhibitors of metalloproteinase Prostate carcinoma Prognosis Survival
Conflict of interest
- DeClerck YA, Alvarez O, Shimada H, Taylor SM, Langley KE (1994) Tissue inhibitors of metalloproteinases: role in tumor progression. Contrib Nephrol 107:108–115Google Scholar
- Gil Ugarteburu R, Rivas del Fresno M, González Rodríguez I, González Arriaga P, López Cima F, Fernández Samoano A, Fernández García I, Benito García P, Muruamendiaraz Fernández V, Tardón A (2010) Matrix metalloproteinase-9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience. Arch Esp Urol 63:125–132PubMedCrossRefGoogle Scholar
- Gonzalez Rodriguez I, Rivas del Fresno M, Gil Ugarteburu R, Gonzalez Arriaga P, Lopez Cima F, Fernandez Samoano A, Muruamendiaraz Fernandez V, Fernandez Garcia I, Perez-Carral JR, Tardon A (2010) Expression of matrix metalloproteinase-9 in prostate cancer. Preliminary experience. Arch Esp Urol 63:119–124PubMedCrossRefGoogle Scholar
- Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Peltaway CA (2000) Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 6:2295–2308PubMedGoogle Scholar
- Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W, Hossfeld DK (2002) Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 13:1550–1557PubMedCrossRefGoogle Scholar
- Nakopoulou L, Gakiopoulou H, Zervas A, Giannopoulou I, Constantinides C, Lazaris AC, Liapis H, Kyriakou G, Dimopoulos C (2001) MMP-3 mRNA and MMP-3 and MMP-1 proteins in bladder cancer: a comparison with clinicopathologic features and survival. Appl Immunohistochem Mol Morphol 9:130–137PubMedCrossRefGoogle Scholar
- Reis ST, Pontes-Junior J, Antunes AA, de Sousa-Canavez JM, Dall’Oglio MF, Passerotti CC, Abe DK, Crippa A, da Cruz JA, Timoszczuk LM, Srougi M, Leite KR (2011) MMP-9 over expression due to TIMP-1 and RECK under expression is associated with prognosis in prostate cancer. Int J Biol Markers 26:255–261PubMedGoogle Scholar
- Stratton M, Dalkin B, Nagle R, Ranger-Moore J, Ahmann F, Bowden G (2006) Matrix metalloproteinase-7 in prostatic fluid versus serum PSA for diagnosis of prostate cancer. In: Prostate cancer symposium general poster session A, ASCO, 24–26 February 2006Google Scholar
- Trudel D, Fradet Y, Meyer F, Harel F, Têtu B (2008) Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum Pathol 39:731–739PubMedCrossRefGoogle Scholar
- Wilson MJ, Jiang A, Wiehr C, Wang X, Sinha AA, Pei D (2004) Limited processing of pro-matrix metalloprotease-2 (gelatinase A) over expressed by transfection in PC-3 human prostate tumor cells: association with restricted cell surface localization of membrane-type matrix metalloproteinase-1. J Androl 25:274–285PubMedGoogle Scholar